Clinical Trials Logo
  1. Home
  2. Chronic Hepatitis
  3. NCT04775797

Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection

Chronic Hepatitis Clinical Trial

Official title:
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AB-836, an HBV Capsid Inhibitor, in Healthy Subjects and Subjects With Chronic HBV Infection

Clinical Trial Summary

This three-part, Phase 1 protocol will be the first clinical study of AB-836. Parts 1 and 2a/b will be a Phase 1a SAD/MAD of AB-836 in healthy adult subjects. Part 3 will be a Phase 1b dose-ranging assessment of AB-836 in non-cirrhotic Chronic Hepatitis B (CHB) subjects.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04775797
Study type Interventional
Source Arbutus Biopharma Corporation
Contact
Status Terminated
Phase Phase 1
Start date June 25, 2021
Completion date November 17, 2022
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01833611 - Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT Phase 4
Completed NCT00771446 - Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) System in Patients With Hepatic Insufficiency Phase 1/Phase 2
Active, not recruiting NCT03731923 - Abbreviated MRI for HCC Surveillance N/A
Recruiting NCT03013556 - Study on an Optimal Antiviral Treatment in HBeAg Positive Chronic Hepatitis B Patients Phase 4
Recruiting NCT05181826 - Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
Active, not recruiting NCT02143180 - Accuracy of RTE for Evaluating Hepatic Fibrosis in Chronic Hepatitis: a Prospective Multicenter Study N/A
Completed NCT00596414 - Sedation and Analgesia for Transjugular Liver Biopsy: A Randomized Double Blind Placebo Controlled Trial Phase 4
Active, not recruiting NCT02772003 - DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection Phase 1
Terminated NCT03487848 - Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection Phase 2
Recruiting NCT02822079 - DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection Phase 1
Recruiting NCT04446832 - VACcination of LIver Transplantation Candidates
Completed NCT01121705 - Efficacy Study of New Therapeutic Schedules in Naive Hepatitis C Virus (HCV) Patients Infected With Genotype 3 (HCV-3) Phase 3
Completed NCT02742597 - Patient-Centred Innovations for Persons With Multimorbidity - Ontario N/A
Completed NCT05678582 - Hepatic Steatosis and Chronic Hepatitis B Virus
Not yet recruiting NCT05062967 - Evaluation of Orthohepevirus C Infection as an Emerging Cause of Zoonotic Origin Disease
Completed NCT01380938 - Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE) Phase 3
Recruiting NCT01413360 - The Effect of High Dose Vitamin C on the Liver Function in Chronic Hepatitis Patients Phase 4
Terminated NCT00496158 - Efficacy and Safety of Clevudine Compared With Adefovir in Patients With Chronic Hepatitis Due to Hepatitis B Virus Phase 3
Terminated NCT00496002 - Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus Phase 3
Completed NCT02789800 - Patient-Centred Innovations for Persons With Multimorbidity - Quebec N/A